How to Sue a Pharmaceutical Company for Defective Prescription Drugs in Maryland

Developing severe gastroparesis after taking a GLP-1 medication like Ozempic, suffering uncontrollable internal bleeding from a defective blood thinner, or receiving a cancer diagnosis linked to contaminated heartburn medications like Zantac prescribed in Baltimore or Silver Spring can upend your health and finances overnight. When a trusted prescription drug causes catastrophic harm, patients often assume their legal claim is a standard medical negligence case against their healthcare provider.

In reality, suing a multinational pharmaceutical company in Maryland is governed by product liability and mass tort law-a completely different legal framework than medical malpractice. Understanding how Maryland's learned intermediary doctrine, federal preemption rules, and Multi-District Litigations (MDLs) work is essential to recovering compensation for your medical bills, lost wages, and pain and suffering.

Pharmaceutical Product Liability vs. Medical Malpractice in Maryland

The first step in any prescription drug injury investigation is distinguishing a defective pharmaceutical product claim from a medical malpractice claim:

• Suing the Pharmaceutical Manufacturer (Product Liability): Targets the drugmaker that researched, formulated, manufactured, and labeled the medication. You are alleging that the chemical compound was defectively designed, contaminated during manufacturing, or marketed with concealed side effects and inadequate warnings.
• Suing the Doctor or Pharmacist (Medical Malpractice): Targets an individual Maryland physician, hospital, or pharmacy (such as when a doctor prescribes a drug despite a known patient allergy on your chart, or a pharmacy dispenses the wrong dosage).

In Maryland, this distinction carries massive procedural consequences. Medical malpractice claims are strictly governed by the Maryland Health Care Malpractice Claims Act (Md. Code, Cts. & Jud. Proc. § 3-2A-04), which requires filing an initial claim with the Health Care Alternative Dispute Resolution Office, Baltimore accompanied by a Certificate of Qualified Expert within 90 days, and subjects damages to specialized medical malpractice caps under the Maryland Courts and Judicial Proceedings Code (Md. Code, Cts. & Jud. Proc. § 3-2A-09). Conversely, suing a pharmaceutical manufacturer is a product liability tort that completely bypasses the Health Care Alternative Dispute Resolution Office and is instead subject to Maryland's broader general personal injury non-economic damages cap under the Maryland Courts and Judicial Proceedings Code (Md. Code, Cts. & Jud. Proc. § 11-108).

Failure to Warn, Hidden Side Effects, and the Learned Intermediary Doctrine

While Maryland recognizes strict product liability under Phipps v. General Motors Corp., 278 Md. 337 (MD Court of Appeals 1976), prescription drugs are treated as unavoidably unsafe products when properly prepared and accompanied by proper directions. Consequently, most dangerous drug lawsuits in Maryland focus on three defect categories: failure to warn, design defects, and manufacturing contamination.

Failure to Warn and Maryland's Learned Intermediary Rule

When a pharmaceutical company downplays clinical trial data or conceals severe side effects-such as failing to warn of vision loss, organ failure, or intestinal paralysis-injured patients bring a failure-to-warn claim. However, Maryland courts enforce the learned intermediary doctrine, as affirmed by the state's highest court in Gourdine v. Crews, 405 Md. 722 (MD Court of Appeals 2008) and Nolan v. Dillon, 261 Md. 516 (MD Court of Appeals 1971).

Under the learned intermediary doctrine, a prescription drug manufacturer has no legal duty to warn the patient directly; instead, its duty is to provide an adequate, truthful warning to the prescribing physician, who acts as a learned intermediary between the manufacturer and the patient. To win a failure-to-warn claim in Maryland, your attorney typically demonstrates two things:

1. The manufacturer's package insert and prescribing information failed to adequately warn the medical community of a known or reasonably scientifically knowable risk.
2. Had the drug company provided an adequate warning, your Maryland doctor either would not have prescribed the drug to you or would have monitored you differently to prevent the injury.

Hidden Side Effects: Brand-Name Drugs vs. Generic Preemption

One of the most critical questions your lawyer will ask is whether your pharmacy dispensed the brand-name medication or a generic equivalent:

• Brand-Name Manufacturers: Under the U.S. Supreme Court's ruling in Wyeth v. Levine, 555 U.S. 555 (US Supreme Court 2009), brand-name drugmakers bear primary responsibility for their label content at all times and can unilaterally strengthen warning labels through federal 'Changes Being Effected' regulations without waiting for prior agency approval. Thus, they can be sued under Maryland law for failing to warn of hidden side effects.
• Generic Drug Preemption: Conversely, in PLIVA, Inc. v. Mensing, 564 U.S. 604 (US Supreme Court 2011), the U.S. Supreme Court held that because federal law requires generic drug labels to be identical to the brand-name label, state-law failure-to-warn claims against generic manufacturers are generally preempted. Exceptions may still exist if a generic batch suffered from chemical contamination, manufacturing adulteration, or off-label promotion.

FDA Recalls, Black Box Warnings, and Adulterated Batch Defects

Although the U.S. Food and Drug Administration, Silver Spring-headquartered right in Montgomery County, Maryland-regulates prescription drug approvals under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355), initial FDA approval does not grant a pharmaceutical company legal immunity from Maryland product liability lawsuits. Furthermore, you do not need an official Class I FDA recall to file a lawsuit; many successful pharmaceutical settlements occur after the FDA mandates a new Black Box Warning or when independent laboratory testing reveals carcinogenic impurities (such as NDMA in ranitidine/Zantac or nitrosamines in blood pressure drugs).

Joining Multi-District Litigations (MDLs) vs. Class Actions from Maryland

Maryland residents harmed by widespread dangerous drugs rarely litigate alone against a pharmaceutical conglomerate, nor do they typically join a traditional class action.

• Why Not a Class Action? In a class action under Federal Rule of Civil Procedure (Fed. R. Civ. P. 23), all members suffered nearly identical, usually small financial losses (such as buying an ineffective over-the-counter supplement) and split an equal payout. Personal injuries from prescription drugs vary wildly from patient to patient, making class certification inappropriate for physical harm.
• How Multi-District Litigation (MDL) Works: Under federal law (28 U.S.C. § 1407), the Judicial Panel on Multidistrict Litigation consolidates thousands of individual dangerous drug lawsuits from across the country before a single federal judge for coordinated pretrial discovery, scientific expert hearings, and bellwether trials. Even when your case is transferred from the U.S. District Court for the District of Maryland, Baltimore or the U.S. District Court for the District of Maryland, Greenbelt into a national MDL, your lawsuit remains an individual claim governed by Maryland substantive tort law, and your settlement payout is graded individually based on the severity of your medical injury.

Step-by-Step Process in Maryland to Sue a Drug Manufacturer

Step 1: Secure Medical Attention and Preserve Medication Packaging

Consult your physician before stopping any prescribed regimen, and get a formal medical diagnosis of your side effects. Save all pill bottles, blister packs, pharmacy receipts, and patient information leaflets, as the National Drug Code (NDC) and Lot Number printed on the bottle identify the exact manufacturer and production facility.

Step 2: Obtain Pharmacy Dispensing Logs and File an Adverse Event Report

Request your complete prescription history from your pharmacy and prescribing records from your Maryland doctor to verify the duration of usage and confirm brand-name versus generic dispensing. Patients or their physicians can also log the adverse reaction with federal regulators using Form FDA 3500B, Federal, U.S. Food and Drug Administration, MedWatch Consumer Voluntary Reporting.

Step 3: File Your Individual Complaint or MDL Short Form Complaint Within 3 Years

Under the Maryland Courts and Judicial Proceedings Code (Md. Code, Cts. & Jud. Proc. § 5-101) and the three-prong discovery rule in Pennwalt Corp. v. Nasios, 314 Md. 433 (MD Court of Appeals 1988), you must file within 3 years of discovering your injury, its link to the drug, and probable manufacturer wrongdoing. Depending on whether an active MDL exists, your lawyer will either file a Short Form Complaint directly into the MDL court, file in the U.S. District Court for the District of Maryland, Baltimore using Form JS-44, Federal, Administrative Office of the U.S. Courts, Civil Cover Sheet, or file in a state venue like the Circuit Court for Baltimore City, Baltimore or the Circuit Court for Montgomery County, Rockville with Form CC-DCM-002, Maryland, Administrative Office of the Courts, Civil - Non-Domestic Case Information Report.

Step 4: Submit the Plaintiff Fact Sheet (PFS) and Participate in Settlement Tiers

Once entered into an MDL, your attorney will help you complete a court-mandated Plaintiff Fact Sheet (PFS)-a standardized sworn questionnaire detailing your medical history, pharmacy records, and damages-alongside HIPAA medical release authorizations. Following bellwether test trials, most successful pharmaceutical MDLs establish a point-based global settlement matrix to compensate verified claimants without requiring you to travel out of Maryland for trial.

How Much Does it Cost in Maryland?

• Court Filing Fees: Filing a federal complaint or direct-filing into an MDL costs $405. If filed in a Maryland Circuit Court, the base civil filing fee is $165 under the Maryland Courts and Judicial Proceedings Code (Md. Code, Cts. & Jud. Proc. § 7-202) plus a $10 to $20 county appearance fee.
• Medical Record Retrieval Fees: Under the Maryland Health-General Code (Md. Code, Health-Gen. § 4-304), Maryland healthcare providers are capped on how much they can charge for electronic and paper medical records, typically costing $25 to $150 per facility.
• MDL Common Benefit Fund Assessments & Attorney Fees: Pharmaceutical mass tort lawyers represent Maryland clients on a strict contingency fee basis (typically 33.3% to 40%), advancing all filing and expert costs upfront. In federal MDLs, the judge also sets a small Common Benefit Fund assessment (typically 6% to 9%) deducted from the gross settlement to reimburse the national Plaintiffs' Steering Committee for shared scientific depositions and trial costs.

How Long Does the Process Take?

Pharmaceutical product liability litigation is a marathon rather than a sprint, typically taking 24 to 48 months from initial intake to settlement distribution. Gathering pharmacy and hospital records and submitting your Plaintiff Fact Sheet takes 3 to 6 months. Coordinated MDL discovery, corporate document production, and scientific admissibility hearings (Daubert hearings) usually span 12 to 24 months, followed by bellwether jury trials that pressure the drugmaker into funding a global settlement program. Because waiting for a television commercial or final settlement announcement can cause you to miss Maryland's 3-year statute of limitations, consult our directory of experienced Maryland pharmaceutical injury lawyers to evaluate and register your claim promptly.

Frequently Asked Questions (FAQ)